Search results for "COMB"

showing 10 items of 7115 documents

Postoperative pain therapy after lumbar disc surgery.

2000

Object. This study was undertaken to determine whether a special postoperative pain administration of tramadol and diclofenac provides any benefits in patients who underwent microsurgical lumbar discectomy.  Methods. The study consisted of 60 patients undergoing microsurgical lumbar discectomy. Patients were randomly divided into two groups based on the postoperative pain management: 1) Group A (n=30): no standardized pain therapy; these patients received on demand different analgesics and at variable dosages which were selected by the neurosurgeons; 2) Group B (n=30): standardized pain therapy with specific dosages of tramadol and diclofenac in regular time intervals during the first 48 ho…

AdultMalemedicine.medical_specialtyDiclofenacAnalgesicPainLumbar vertebraeDiclofenacPostoperative ComplicationsmedicineHumansHerniaIntervertebral DiscTramadolAgedPain MeasurementLumbar Vertebraemedicine.diagnostic_testbusiness.industryAnti-Inflammatory Agents Non-SteroidalInterventional radiologyMiddle Agedmedicine.diseaseSurgeryAnalgesics OpioidIntervertebral diskmedicine.anatomical_structureAnesthesiaSurgeryDrug Therapy CombinationFemaleNeurology (clinical)TramadolComplicationbusinessmedicine.drugDiskectomyActa neurochirurgica
researchProduct

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.

2006

Summary. Aim: A multicenter randomized open-label crossover prospective trial was designed to compare the efficacy, safety, and cost of standard and high dosages of recombinant factor VIIa (rFVIIa) for home treatment of hemarthroses in hemophiliacs with inhibitors. Methods: Patients were instructed to treat, within 6 h from the onset of bleeding, four consecutive hemarthroses of ankles, knees, or elbows, either with the rFVIIa standard dose of 90 μg kg−1 (repeated as necessary every 3 h) or with a single high dose of 270 μg kg−1. Patients who did not achieve a clinical success within 9 h continued rFVIIa treatment with repeated standard doses. Response to treatment was assessed for up to 48…

AdultMalemedicine.medical_specialtyDoseAdolescentVisual analogue scaleFactor VIIaHemophilia Alaw.inventionRandomized controlled triallawSingle high doseHemarthrosisMedicineHumansProspective StudiesProspective cohort studyChildCross-Over Studiesbiologybusiness.industryInfantHematologyMiddle AgedCrossover studyRecombinant ProteinsSurgeryRegimenRecombinant factor VIIaChild Preschoolbiology.proteinSafetybusinessJournal of thrombosis and haemostasis : JTH
researchProduct

Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML …

1990

Alpha- and gamma-interferons have been shown to actively suppress hematopoiesis in patients in the chronic phase of chronic myelogenous leukemia in vitro and in vivo. Since both interferons act through different receptors on their hematopoietic target cells, they are expected to be capable of independently inhibiting abnormal blood cell development in patients with chronic myelogenous leukemia. We have utilized recombinant human interferon alfa-2c to treate 11 patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase, who were resistant to previous interferon gamma therapy. Ten of the patients were evaluable for hematologic, cytogenetic and molecular-genet…

AdultMalemedicine.medical_specialtyDrug ResistanceAlpha interferonBiologyCytogeneticsInterferon-gammaInterferonhemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansInterferon gammaInterferon alfaHematologybreakpoint cluster regionHematologyGeneral MedicineMiddle Agedmedicine.diseaseHematologic ResponseRecombinant ProteinsImmunologyInterferon Type ICancer researchDrug EvaluationFemalemedicine.drugChronic myelogenous leukemiaBlut
researchProduct

Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

2014

Abstract Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismContext (language use)Pilot ProjectsType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucagon-Like Peptide 1Internal medicineDiabetes mellitusMedicineHumansHypoglycemic AgentsProspective StudiesAgedbusiness.industryLiraglutideBiochemistry (medical)Liraglutide Heme oxygenase Lipid peroxidation Ghrelin Type-2 diabetesOriginal ArticlesLiraglutideMiddle Agedmedicine.diseaseGhrelinMetformin3. Good healthMetforminOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2GhrelinDrug Therapy CombinationFemaleGlycated hemoglobinbusinessOxidative stressHeme Oxygenase-1medicine.drug
researchProduct

Lipoprotein phenotype and insulin resistance in familial combined hyperlipidemia.

2001

The study objective was to investigate the relationship of insulin resistance (IR) with the lipoprotein phenotype in familial combined hyperlipidemia (FCH). Thirty-seven FCH men diagnosed by clinical and biochemical criteria and classified as lipoprotein phenotype IIa (n = 9), IIb (n = 17), or IV (n = 11) were compared with a healthy control group of 30 men of similar age, body mass index (BMI), waist to hip ratio (WHR), and systolic and diastolic blood pressure. In all subjects, the plasma lipoprotein profile and baseline and post-oral glucose tolerance test (OGTT) glucose and insulin plasma values were measured. An intravenous glucose tolerance test was performed and IR was studied by the…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentLipoproteinsHyperlipidemia Familial CombinedEndocrinologyWaist–hip ratioInsulin resistanceReference ValuesInternal medicineInsulin SecretionmedicineHumansInsulinPancreatic hormoneHypertriglyceridemiaGlucose tolerance testmedicine.diagnostic_testChemistryInsulinHypertriglyceridemiaArea under the curveGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyPhenotypeInsulin ResistanceLipoproteinMetabolism: clinical and experimental
researchProduct

Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.

2018

Abstract Introduction Chronic Hepatitis C virus infection (HCV) is associated with extrahepatic manifestations and an increased prevalence in cardiovascular disease. New direct acting antivirals (DAA) have revolutionized HCV treatment with high rates of sustained virological response (SVR). Recently it was demonstrated, that SVR reduces morbidity and overall mortality more than can be solely explained by hepatic effects, suggesting that treatment with DAA also affects cardiovascular disease. The aim of this pilot study was to identify possible underlying mechanisms behind the HCV-associated cardiovascular mortality reported by others. Methods and results 20 HCV patients (10 genotype GT1, 10…

AdultMalemedicine.medical_specialtyEndotheliumInflammationPilot Projects030204 cardiovascular system & hematologymedicine.disease_causeSystemic inflammationGastroenterologyAntiviral AgentsCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceInterferonInternal medicineRibavirinClinical endpointmedicineHumansbusiness.industryRibavirinHepatitis C ChronicMiddle Agedmedicine.diseasemedicine.anatomical_structureTreatment Outcomechemistry030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleEndothelium VascularInterferonsmedicine.symptomCardiology and Cardiovascular MedicinebusinessOxidative stressmedicine.drugInternational journal of cardiology
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Magnesium Responsiveness to Insulin and Insulin-Like Growth Factor I in Erythrocytes from Normotensive and Hypertensive Subjects

1998

Depletion of intracellular free magnesium (Mg(i)) is a characteristic feature of insulin resistance in essential hypertension, but it is not clear to what extent low Mg(i) levels contribute to insulin resistance, result from it, or both. As insulin-like growth factor I (IGF-I) may improve insulin resistance, we investigated whether this peptide could similarly improve Mg(i) responsiveness to insulin in hypertension, and whether this effect was related to any direct IGF-I effect on Mg(i). 31P-Nuclear magnetic resonance spectroscopy was used to measure Mg(i) in erythrocytes from 13 fasting normotensive and 10 essential hypertensive subjects before and 30, 60, and 120 min after incubation with…

AdultMalemedicine.medical_specialtyErythrocytesMagnetic Resonance SpectroscopyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryEssential hypertensionBiochemistryInsulin-like growth factorEndocrinologyInsulin resistanceReference ValuesInternal medicinemedicineHumansInsulinMagnesiumInsulin-Like Growth Factor IPancreatic hormoneDose-Response Relationship Drugbusiness.industryInsulinGrowth factorBiochemistry (medical)Middle Agedmedicine.diseaseRecombinant ProteinsPathophysiologyRed blood cellEndocrinologymedicine.anatomical_structureHypertensionFemalebusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center bi…

2011

Abstract Background Cetuximab plus irinotecan/folinic acid/5-fluorouracil (5-FU) (IF) was evaluated as first-line treatment of patients with advanced gastric cancer and gastroesophageal junction tumors. Preplanned analyses of the influence of tumor biomarkers on treatment outcome were carried out. Patients and methods Patients received weekly cetuximab (400 mg/m2 on day 1, subsequently 250 mg/m2) plus irinotecan (80 mg/m2) and a 24-hour continuous infusion of folinic acid (200 mg/m2) and 5-FU (1500 mg/m2) on days 1, 8, 15, 22, 29 and 36 of a 50-day cycle, until progressive disease (PD). Results The most common grade 3/4 toxic effects in 49 patients were diarrhea (15%) and skin toxic effects…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.drug_classMedizinLeucovorinPhases of clinical researchCetuximabAntibodies Monoclonal HumanizedIrinotecanAntimetaboliteGastroenterologyFolinic acidStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProgression-free survivalAgedCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanTreatment OutcomeOncologyFluorouracilCamptothecinFemaleFluorouracilbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: The SURGE 2 practice-based study

2013

SURGE 2, a large-scale, practice-based study in 10 countries, evaluated the effects of telmisartan alone or with hydrochlorothiazide (HCTZ) on morning (06:00 – 11:59) home blood pressure (HBP) control. Hypertensive patients (clinic blood pressure [BP] 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12.5 mg for 8 weeks. Treatment could be adjusted if clinic BP remained 140/90 mmHg. Clinic BP was measured in the morning prior to medication, and seated HBP monitoring was performed, three times per day, 2 days per week. A total of 25,882 patients were included (71% were previously using antihypertensives). There was a statistically signifi cant (all p 0.00…

AdultMalemedicine.medical_specialtyEveningAdolescentDiastoleBlood PressureBenzoatesYoung AdultHydrochlorothiazideInternal medicineInternal MedicinemedicineHumansProspective StudiesTelmisartanProspective cohort studyAdverse effectAntihypertensive AgentsMorningAgedAged 80 and overbusiness.industryHome blood pressure monitoring hydrochlorothiazide morning blood pressure control telmisartanGeneral MedicineMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedDrug CombinationsEndocrinologyBlood pressureHydrochlorothiazideAnesthesiaHypertensionBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct